NASDAQ: LSTA - Lisata Therapeutics, Inc.

Rentabilität für sechs Monate: -21.67%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Lisata Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.

weitere details
Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 1999-03-01
ISIN US1280583022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lisata.com
Цена ао 2.43
Preisänderung pro Tag: -2.51% (2.4104)
Preisänderung pro Woche: -1.26% (2.38)
Preisänderung pro Monat: -1.67% (2.39)
Preisänderung über 3 Monate: -22.19% (3.0201)
Preisänderung über sechs Monate: -21.67% (3)
Preisänderung pro Jahr: -24.68% (3.12)
Preisänderung über 3 Jahre: +201.28% (0.78)
Preisänderung über 5 Jahre: -0.4237% (2.36)
Preisänderung seit Jahresbeginn: -20.07% (2.94)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0.1067 10
P/BV 0.477 10
P/E 0 0
EV/EBITDA -0.0219 0
Gesamt: 6.25

Effizienz

Name Bedeutung Grad
ROA, % -38.1 0
ROE, % -43.28 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.012 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 727.43 10
Rentabilität Ebitda, % 32.22 5
Rentabilität EPS, % -91.16 0
Gesamt: 3.4
Weitere Details

Institutionen Volumen Aktie, %
Bml Capital Management, LLC 269839 3.25
Vanguard Group Inc 176965 2.13
Renaissance Technologies, LLC 97222 1.17
Blackrock Inc. 56250 0.68
Geode Capital Management, LLC 43390 0.52
Susquehanna International Group, LLP 33749 0.41
State Street Corporation 14348 0.17
Citadel Advisors Llc 14131 0.17
Cook Wealth Management Group LLC 12175 0.15
HighTower Advisors, LLC 10044 0.12



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, CEO & Director 1.16M 1957 (68 Jahre)
Dr. Kristen K. Buck M.D. Executive VP of R&D and Chief Medical Officer 938.42k 1974 (51 Jahr)
Mr. James Nisco Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer N/A 1971 (54 Jahr)
Mr. Tariq Imam Vice President of Business Development & Operations and Corporate Counsel N/A
Mr. Gregory S. Berkin Chief Information Officer N/A
Mr. John D. Menditto Vice President of Investor Relations & Corporate Communications N/A
Ms. Gail Holler Vice President of Human Resources N/A 1959 (66 Jahre)
Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs 350.55k 1956 (69 Jahre)

Adresse: United States, Basking Ridge. NJ, 110 Allen Road - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.lisata.com